The LEED Gold-certified facility features flexible laboratory configurations and advanced mechanical and utility systems, enabling researchers to conduct intricate scientific research.
The site will continue operating as a subsidiary under the Syntagon name, maintaining its established brand presence in the pharmaceutical manufacturing sector.
The company formalized its commitment with South Korea’s Ministry of Health and Welfare to enhance the bio-healthcare industry by supporting international clinical trials and advancing research for innovative medicines.
This strategic approach aligns with President Bola Tinubu’s broader vision to unlock the healthcare value chain by empowering local pharmaceutical industries.
The new generic formulation matches the composition of Celgene’s original Pomalyst medication and comes in four different strengths: 1mg, 2mg, 3mg, and 4mg.
The new manufacturing hub represents a core strategic priority for PharmaEssentia as the company works to strengthen its supply chain, increase production flexibility, and diversify its geographic footprint.
The Japanese pharmaceutical giant expects the transaction to conclude during the first quarter of fiscal 2026, subject to standard regulatory conditions.
The EMA will now proceed with a final decision, potentially clearing the way for global distribution of this combination immunization.
The tabletting facility in Athlone represents a cornerstone of Novo Nordisk’s long-term strategy to strengthen its presence in Ireland and enhance its global manufacturing footprint.
The agreement grants Novo Nordisk licensing rights to select oral drug-delivery technologies from Vivtex.